MedTrace Logo

Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)

NCT00464295 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2007-12-14

No results posted yet for this study

Summary

In patients with unresectable/advanced Hepatocellular Carcinoma receiving Capecitabin, we anticipate that the proposed chemotherapy will have a delay in progression of the disease . It is also expected that proposed chemotherapy will have acceptable toxicity and Quality of life.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

Capecitabine in HCC

Sponsors & Collaborators

  • Aga Khan University

    lead OTHER

Principal Investigators

  • Muhammad K Anis, MD · Aga Khan University

  • Zaigham Abbas, MD · Aga Khan University

  • Wasim Jafri, MD · Aga Khan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Completion
2007-10-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00464295 on ClinicalTrials.gov